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Summary. The antibody response and delayed type hyper- 
sensitivity reaction to commercially available trivalent influ- 
enza vaccine in 159 patients with diabetes mellitus was com- 
pared with response and reaction in 28 healthy volunteers. A 
correction for prevaccination titres was made. No differences 
were found between diabetic patients and control subjects 
with respect to antibody response to the three vaccine strains 
as measured by the difference between geometric mean titres 
of post- and prevaccination sera. In Type 1 (insulin-depen- 
dent) diabetic patients the incidence of non-responders to
two vaccine components was significantly increased (p< 
0.05). The delayed type hypersensitivity reaction to influenza 
antigen was significantly decreased in patients with high con- 
centrations of glycosylated haemoglobin (p<0.01). These 
findings suggest a role for impaired immune response in the 
increased influenza morbidity and mortality in patients with 
diabetes mellitus. Implications for therapy and vaccination 
strategy are discussed. 
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Infections with influenza carry a high morbidity and 
mortality rate in patients with diabetes mellitus [1-3]. 
The increased risk of complications in these patients is 
generally ascribed to the occurrence of diabetic ketoac- 
idosis [4] and secondary bacterial infection, mainly by 
Staphylococcus aureus [5]. Patients with diabetes melli- 
tus are often carriers of Staphylococcus aureus, and 
they have been shown to have an impaired immune re- 
sponse to this micro-organism [6, 7]. 
In order to prevent these complications, annual 
vaccination of diabetic patients is recommended. To 
accomplish protection against influenza, vaccination 
should induce high antibody titres against the viral 
haemagglutinin [8]. Simultaneously stimulated cellular 
immunity, though not protective, might contribute to 
the recovery from infections with influenza viruses [9]. 
Poor antibody response to influenza vaccination 
has been demonstrated in various risk groups, such as 
renal transplant patients [10], patients with malignant 
diseases [11, 12] and in the aged [13]. 
In order to evaluate the immune response to influ- 
enza antigen in both Type 1 (insulin-dependent) and 
Type 2 (non-insulin-dependent) diabetic patients, we 
studied the antibody production and delayed type hy- 
persensitivity reaction after vaccination with a trivalent 
influenza vaccine. 
Subjects and methods 
Subjects 
Patients tudied were attending the outpatient clinic of the Depart- 
ment of Internal Medicine of the Diakonessen Hospital, Utrecht, 
The Netherlands. Patients were considered to be Type I if there had 
been documented ketoacidosis and/or abrupt onset of symptoms re- 
quiting insulin therapy at age < 40 years and Type 2 if there had 
been protracted treatment with diet or oral therapy at age > 40 years. 
The study population consisted of 27 patients with Type 1 diabetes 
mellitus, 18 men and 9 women (mean age 39.3 + 13.6 years, mean du- 
ration of disease 16.5 _+ 14.0 years) and 120 patients with Type 2 dia- 
betes mellitus, 51 men and 69 women (mean age 65.3 _+ 10.0 years, 
mean duration of disease 10.3 +7.1 years). Among 12 patients, 5 men 
and 7 women (mean age 61.9_+7.4 years), the type of' diabetes was 
unknown. In Type 1 diabetic patients, 5 had known cardiovascular 
complications, 3 were treated for retinopathy and 1 had marked neu- 
ropathy. Among Type 2 patients 37% were more than 10% over- 
weight and 25% had major cardiovascular complications. Retinopa- 
thy was diagnosed in 16 and neuropathy in 13% of Type 2 diabetic 
patients. Control subjects were 28 healthy volunteers, 13 men and 
15 women (mean age 50.8 _+ 17.0 years). Participants were excluded if
they were allergic to egg protein or when febrile on the day of vacci- 
nation. Written consent was obtained from all participants and ap- 
proval for the study was obtained from the Ethical Committee of the 
University Hospital Dijkzigt. 
Vaccine: dosage and administration 
Trivalent purified whole virus influenza vaccine (Duphar-Nederland, 
Amsterdam, The Netherlands) containing 10 Ixg haemagglutinin 
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(HA) A/Philippines/2/82 (H3N2), 10 ~g HA A/Chile/I/83 (HiNt) 
and 15 gg HA B/USSR/100/83 was administered in0.5 ml doses in- 
tramuscularly in the upper arm. To induce a delayed type hypersen- 
sitivity reaction, an 0.t ml dose of the same vaccine (diluted 1 : 1 with 
phosphate buffered saline) was inoculated into the skin of the volar 
aspect of the forearm. 
Laboratory investigations and calculations 
Blood samples were obtained prior to administration of vaccine and 
again 14 days later. Sera were separated immediately after blood col- 
lection and clotting and stored at -20 ~ until titration. 
Influenza strains were propagated in embryonated hen's eggs. 
Because of the low avidity of the influenza B virus, infectious egg 
fluids of this strain were treated with aether according to Berlin et al. 
[14] and the watery phase was used in the serologic tests. 
Serum haemagglutination inhibition (HI) titres were determined 
twice by standard methods [15] simultaneously in pre- and post-vac- 
cination sera. Titres were expressed as reciprocals of the dilution 
showing 50% haemagglutination inhibition with 3 haemagglutina- 
tion units of the antigen. From the results of the two determinations 
per serum and per antigen, the geometric means were used for fur- 
ther calculations. Negative titres (< 9) were arbitrarily regarded as 5. 
With the method used, protection against influenza is thought to 
be associated with an HI titre of 100 for influenza A [8]. No protec- 
tion threshold is known for aether-treated influenza B strains. For 
this study an HI titre of 100 was assumed to be protective. 
Among diabetic patients and control subjects, those with prevac- 
cination titres above 100 were excluded separately for each antigen. 
The serologic response upon vaccination was expressed using the 
following criteria: the response rate (i. e. the proportion of subjects 
with a 4-fold or greater titre increase after vaccination); the protec- 
tion rate (i. e. the proportion of subjects exceeding the threshold titre 
of 100 after vaccination); the mean-fold increase (i. e. the difference 
between the logarithmated geometric mean titres of post- and pre- 
vaccination sera). 
peutic regimen. Results are presented for the three vac- 
cine strains separately in Tables 1-3. A l though patients 
with Type 1 diabetes and those with Type 2 diabetes 
treated with a diet only tended to have lower ant ibody 
responses after vaccinat ion as compared to control 
subjects, differences in mean-fo ld increase were not 
statistically significant. The established protection rate 
was high for the H3N2 strain (Table 1), reaching 90% 
in control subjects and 85% in diabetic patients. Pro- 
tection rates for the other two vaccine components,  
however, were considerably lower: 66 and 64% for 
H1Na and 50 and 57% for the inf luenza B strain (con- 
trol subjects and patients, respectively). Differences 
were not statistically significant. 
In  compar ison with control  subjects, the incidence 
of  patients showing a 4-fold or greater titre rise was 
substantially lower in Type 1 diabetes for the H3N2 
and influenza B vaccine components  (100 vs 78% and 
80 vs 44%, respectively, p< 0.05). A significantly lower 
incidence of  patients with a 4-fold or greater titre in- 
crease to the influenza B strain was also shown for pat- 
ients treated with insulin, a major  part of  whom had 
Type I diabetes (46 vs 80% in control  subjects, p< 
0.01). 
For patients treated with diet only, the incidence of  
patients with a 4-fold or greater titre increase was sig- 
nif icantly lower for the H3N2 component  (78 vs 100% 
in control subjects, p<0.05) .  There was no correlation 
between ant ibody product ion or response rate and the 
concentrat ion of  HbAtc. 
Glycosylated haemoglobin 
The percentage of glycosylated haemoglobin (HbAac) on the day of 
vaccination was determined by a commercially available column test 
(Bio Rad Laboratories, Richmond, Calif, USA). In short, a small 
quantity of whole blood is mixed with a haemolysis reagent. An ali- 
quot of the haemolysate is then applied to a weakly acidic cation ex- 
change resin in a disposable column. The HbAla and HbAlb frac- 
tions are first eluted by adding a buffer. The HbAlc fraction is then 
eluted separately by adding a second dilution/developing reagent. 
The relative % concentration of HbAlc is determined spectrophoto- 
metrically. 
Delayed type hypersensitivity reaction (D THR) 
DTHR was read after 24 h. Quantification of the test was achieved 
by calculating the area of induration as the product of two diameters 
at right angles. Diameters were measured as described previously by 
Sokal [17]. 
Statistical analysis 
Data are presented as mean+ SD. Differences in qualitative mea- 
sures were tested for significance by the chi-square test, and in 
quantitative measures by the Wilcoxon rank test. 
Results 
Seroresponse 
The outcome of  the serologic determinations was cal- 
culated for type of  diabetes mellitus and for the thera- 
Delayed type hypersensitivity reaction (D THR) 
In order to establish a correlation between the DTHR 
and the metabol ic state, all 159 patients were divided 
into two groups according to the concentrat ion of  gly- 
cosylated haemoglobin:  HbAtc 4-6.5% (within normal  
limits), and > 6.5%. 
The largest indurat ion was demonstrated in control 
subjects: 360 mm 2 (_+ 246). In patients with HbAt  val- 
ues within normal  limits (HbAI<6.5%) ,  the DTHR 
was similar to that in control subjects. In compar ison 
with control subjects, the DTHR in patients with an 
HbAao>6.5% was significantly decreased (p<0.01).  
Results are shown in Figure 1. 
Discussion 
From a previous study it was concluded that patients 
with well control led diabetes mellitus respond normal-  
ly to inf luenza immunisation. The populat ion studied, 
however, was small and prevaccinat ion titres were con- 
siderably higher in control subjects, for which no cor- 
rection was made [18]. In the present study a correction 
was included for prevaccinat ion titres. It is shown that, 
at least in patients with Type i diabetes, there is an in- 
creased incidence of  non-responders to two of  the 
three vaccine components.  Humora l  immune response 
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Table 1. Serologic response to the H3N2 vaccine component in control subjects and in patients with diabetes mellitus 
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Control Diabetic patients 
subjects 
Total Type 1 Type 2 Oral therapy Diet Insulin 
(n= 28) (n= 159) (n= 27) (n= 120) (n= 57) (n= 20) (n= 80) 
Number of subjects with 8 49 9 36 17 2 29 
prevaccination titre > 100 
Mean HbA~c% (+SD) 5.0(+0.4) 7.7(_+1.5) 7.9(_+1.5) 7.7(_+1.5) 7.8(_+1.3) 6.8(_+1.1) 8.1(_+1.5) 
Subjects tudied 20 110 18 84 40 18 31 
Mean-fold increase 1.55( _+ 0.74) 1.53( + 0.79) 1.38( -+ 0.72) 1.56( _+ 0.79) 1.63( _+ 0.74) 1.33( _+ 0.82) 1.53( _+ 0.81) 
(-+SO) 
% of subjects with post- 90 85 94 83 85 77 88 
vaccination titre > 100 
% of subjects with 4-fold 100 86 78 a 87 88 78 a 87 
or greater titre increase 
Data of 12 patients whose type of diabetes was unknown and of 2 patients with both insulin and oral therapy are not shown, a Different from 
controls p< 0.05 
Table 2. Serologic response to the H1N1 vaccine component in control subjects and in patients with diabetes mellitus 
Control Diabetic patients 
subjects 
Total Type 1 Type 2 Oral therapy Diet Insulin 
(n = 28) (n = 159) (n = 27) (n = 120) (n = 57) (n = 20) (n = 80) 
Number of subjects with 4 14 4 8 6 1 7 
prevaccination titre > 100 
Mean HbA~c% (+_SD) 5.0(+0.5) 7.7(+1.5) 7.5(+1.6) 7.8(_+1.5) 7.9(+1.4) 6.6(+1.1) 8.1(_+1.6) 
Subjects tudied 24 145 23 112 51 19 73 
Mean-fold increase 1.04( + 0.61) 1.04( _+ 0.68) 1.07( -+ 0.67) 1.04( _+ 0.68) 1.17( + 0.61) 0.79( _+ 0.62) 1.00( _+ 0.63) 
(___SD) 
% of subjects with post- 66 64 73 62 70 47 64 
vaccination titre > 100 
% of subjects with 4-fold 67 65 70 67 69 58 58 
or greater titre increase 
Data of 12 patients whose type of diabetes was unknown and of 2 patients with both insulin and oral therapy are not shown 
Table 3. Serologic response to the influenza B vaccine component in control subjects and in patients with diabetes mellitus 
Control Diabetic patients 
subjects 
Total Type I Type 2 Oral therapy Diet Insulin 
(n = 28) (n = 159) (n = 27) (n = 120) (n = 57) (n = 20) (n = 80) 
Number of subjects with 4 33 4 25 8 6 19 
prevaccination titre > 100 
Mean HbA1o% (+SD) 5.0(+0.5) 7.8(+1.5) 7.4(+1.5) 7.9(+1.4) 8.0(+1.5) 7.0(+l.1) 8.0(_+1.5) 
Subjects tudied 24 126 23 95 49 14 61 
Mean-fold increase 0.95( _+ 0.52) 0.87( _+ 0.61) 0.66( _+ 0.58) 0.90( _+ 0.58) 0.99(+ 0.61) 0.72( + 0.42) 0.79( + 0.63) 
(+SD) 
% subjects with post-vacci- 50 57 56 58 63 35 63 
nation titre > 100 
% subjects with 4-fold or 80 61 44 a 65 76 65 46 b 
greater titre increase 
Data of 12 patients whose type of diabetes was unknown and of 2 patients with both insulin and oral therapy are not shown, a Different from 
control subjects p< 0.05; b p< 0.01 
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Fig. t. Mean area of induration after inoculation of influenza vac- 
cine in healthy control subjects (C) and in patients with diabetes 
mellitus. Patients were arbitrarily divided into two groups according 
to the percentage of HbAlc: group I, 4-6.5% (n=35); group II, > 
6.5%(n= 159). *different from control subjects, p< 0.01 
to influenza vaccination has been shown to be im- 
paired in the elderly [13]; however, as control subjects 
(mean age 50.8_+ 17.0 years) were older than Type 1 
diabetic patients (mean age 34.4_+ 13.6 years), age can- 
not be held responsible for the increased incidence of 
non-responders among Type 1 patients. 
Antibody formation against he influenza ntigen is 
a T-cell dependent phenomenon. In experimental ni- 
mals the humoral immune response is impaired if the 
helper effect of T cells is lacking [19]. In patients with 
Type I diabetes, T-cell depletion has recently been 
demonstrated [20]. This may explain the increased inci- 
dence of non-responders to influenza antigen, while 
antibody response to pneumococcal polysaccharide, 
which may proceed independently of T-cell help, is not 
decreased [21]. 
The number of patients unable to acquire a protec- 
tive antibody level against he influenza B and H1N1 
vaccine components is substantial. This is an important 
outcome, considering the high incidence of other risk 
factors such as cardiovascular diseases, especially in 
elderly diabetic patients. Barker and Mullooly [1] 
showed that influenza mortality is highest in patients 
who have cardiovascular disease in combination with 
either diabetes or chronic pulmonary disease. There- 
fore, a booster immunisation after at least 4 weeks 
seems to be advisable in patients with diabetes melli- 
tus. However, results of booster vaccination in other 
risk groups are disappointing [10, 22]. 
Decreased DTHR to candida in diabetic patients 
has been previously demonstrated [23]. In the same 
study no decreased DTHR was found for a viral anti- 
gen (mumps). Mahmoud et al. [24] showed that de- 
creased cellular hypersensitivity n diabetic mice could 
be restored with insulin treatment. Our findings of a 
decreased DTHR in patients with high HbAlo values 
and not in patients with HbAtcvalues within normal 
limits suggest that optimal regulation might restore the 
DTHR in humans. 
The function of T cells which mediate the DTHR 
in influenza infections is not clear. In mice these cells 
were found in the lungs after infection with an influen- 
za A virus, the concentration of cells being correlated 
with the amount of virus administered [25]. For recov- 
ery from the infection, however, the cytotoxic T cell 
and natural killer cell are probably more important [9]. 
Until now it was assumed that the main risks of in- 
fluenza infection in patients with diabetes mellitus lie 
in the occurrence of ketoacidosis [4] and secondary 
bacterial infection [5]. From this study it can be con- 
cluded that impaired immune response to the influen- 
za virus itself may contribute to increased morbidity 
and mortality. 
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